PHAT on XNAS, Health Care, Phathom Pharmaceuticals, Inc., job postings
Measures activity, not value. Not investment advice.
Revenue jumped 71% to $84.7M in the quarter, but the stock is down 68% in a year.
BadNet loss $83M over 12 months, free cash flow negative $21M
BadShort interest at 11% of shares, 4.8 days to cover
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
expected around 6 Jan 2027 (an estimate: a year ago it reported on 7 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $84.7M, net loss $13.9M.
31 Dec 2021RevenueNet incomeNet losstallest bar $94.3M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$84.7M
-$13.9M
30 Jun 2026
$74.3M
-$17.6M
31 Mar 2026
$58.3M
-$30.4M
31 Dec 2025
$57.6M
-$21.1M
30 Sep 2025
$49.5M
-$30.0M
30 Jun 2025
$39.5M
-$75.8M
31 Mar 2025
$28.5M
-$94.3M
31 Dec 2024
$29.7M
-$74.5M
30 Sep 2024
$16.4M
-$85.6M
30 Jun 2024
$7.3M
-$91.4M
31 Mar 2024
$1.9M
-$82.9M
31 Dec 2023
$682K
-$79.6M
30 Sep 2023
$0
-$43.2M
30 Jun 2023
$0
-$41.0M
31 Mar 2023
$0
-$37.8M
31 Dec 2022
–
-$55.0M
30 Sep 2022
–
-$51.1M
30 Jun 2022
–
-$50.9M
31 Mar 2022
–
-$40.7M
31 Dec 2021
–
-$35.8M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$274.9M
$147.2M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+87%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$83.0M
-$274.6M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$1.01
-$3.77
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
80.7%
87.2%
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-9.3%
-145%
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-30.2%
-187%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
–
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$21.0M
-$225.4M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$184.6M
$135.2M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$165.5M
$207.1M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$19.0M (net cash)
$71.9M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
–
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
1.4
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
1.3
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
–
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+71%
$84.7M vs $49.5M (quarter ended 30 Sep 2026)
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-1.2%
159 13F filers vs 161
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
86%
69.9M shares held by 13F filers (30 Sep 2026) of 81.3M outstanding (27 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
11%
9.2M shares sold short (30 Oct 2026) of 81.3M outstanding (27 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
4.8
9.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-5.9%
9.8M shares sold short in the report before, 9.2M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
53%
53% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 51%
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$60K
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
14
14 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
14×
14 articles in the last 7 days; its usual week has 1.
Price $4.66 on 20 Nov 2026, -68% over 12 months (12-month range $4.66 to $18.08)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $157K).Revenue per quarter. Revenue $84.7M in the latest quarter, +71% on a year earlier.Capital spending per quarter. Capital spending $110K in the latest quarter, +307% on a year earlier.Institutional holders (13F filers). 159 13F filers reported holding it in the latest 13F quarter, +25% on a year earlier.Lobbying spend. Lobbying spend: $60K published in the last 12 months, +33% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.
Quarter ended 31 Mar 2023: $0; public on 10 May 2024
Quarter ended 30 Jun 2023: $0; public on 9 Aug 2024
Quarter ended 30 Sep 2023: $0; public on 8 Nov 2024
Quarter ended 31 Dec 2023: $682K; public on 8 Mar 2024
Quarter ended 31 Mar 2024: $1.9M; public on 10 May 2024
Quarter ended 30 Jun 2024: $7.3M; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $16.4M; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $29.7M, +4250% on a year earlier; public on 7 Mar 2025
Quarter ended 31 Mar 2025: $28.5M, +1392% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $39.5M, +439% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $49.5M, +203% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $57.6M, +94% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $58.3M, +104% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $74.3M, +88% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $84.7M, +71% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $100K, -19% on a year earlier; public on 2 Mar 2022
Quarter ended 31 Mar 2022: $67K, -60% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $428K, +851% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $134K, +857% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $412K, +312% on a year earlier; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $214K, +219% on a year earlier; public on 11 May 2023
Quarter ended 30 Sep 2023: $939K, +601% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $475K, +15% on a year earlier; public on 8 Mar 2024
Quarter ended 31 Mar 2024: $40K, -81% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $46K; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $44K, -95% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $5K, -99% on a year earlier; public on 7 Mar 2025
Quarter ended 31 Mar 2025: $18K, -55% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $97K, +111% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $27K, -39% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $87K, +1640% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $61K, +239% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $44K, -55% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $110K, +307% on a year earlier; public on 30 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 76; public on 14 Feb 2022
31 Mar 2022 report: 80; public on 16 May 2022
30 Jun 2022 report: 90; public on 15 Aug 2022
30 Sep 2022 report: 89; public on 14 Nov 2022
31 Dec 2022 report: 83; public on 14 Feb 2023
31 Mar 2023 report: 82; public on 15 May 2023
30 Jun 2023 report: 97; public on 14 Aug 2023
30 Sep 2023 report: 102; public on 14 Nov 2023
31 Dec 2023 report: 109; public on 14 Feb 2024
31 Mar 2024 report: 111; public on 15 May 2024
30 Jun 2024 report: 108; public on 14 Aug 2024
30 Sep 2024 report: 128; public on 14 Nov 2024
31 Dec 2024 report: 142; public on 14 Feb 2025
31 Mar 2025 report: 135; public on 15 May 2025
30 Jun 2025 report: 114; public on 14 Aug 2025
30 Sep 2025 report: 127; public on 14 Nov 2025
31 Dec 2025 report: 167; public on 17 Feb 2026
31 Mar 2026 report: 169; public on 15 May 2026
30 Jun 2026 report: 161; public on 14 Aug 2026
30 Sep 2026 report: 159; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Apr 2025: $15K published
Quarter from 1 Jul 2025: $15K published
Quarter from 1 Oct 2025: $15K published
Quarter from 1 Jan 2026: $15K published
Quarter from 1 Apr 2026: $15K published
Quarter from 1 Jul 2026: $15K published
Quarter from 1 Oct 2026: $15K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $84.7M (30 Sep 2026), 1.9× its normal quarter; higher than 100% of its own history.
Reported lobbying spend: $15K in Q3 2026, $15K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
6 Feb 2025
New
Jeffrey J. Kimbell & Associates, Inc.for Phathom Pharmaceuticals
Two or more unrelated kinds of records unusual within 30 days
11 Mar 2025confirmed
Confirmed across sources Institutional holdings and Filings + Financials
Phathom Pharmaceuticals(PHAT): saw 27 13F filers open a new position in the quarter ended 31 Dec 2024, 2.1× the same quarter last year, while it reported revenue of $29.7M for the quarter ended 31 Dec 2024, 43× the same quarter last year. Two unrelated kinds of activity within 21 days.
Institutional holdings: Many funds opening a new position, became public on 14 Feb 2025
Financials: Quarterly revenue change, became public on 11 Mar 2025
The quarter ended 31 Dec 2024 against the 8 quarters before it.
this quarterearliernormal: 13.5See the evidence (2 changes)
Institutional holdings: Many funds opening a new position became public on 14 Feb 2025
Phathom Pharmaceuticals saw 27 13F filers open a new position in the quarter ended 31 Dec 2024, 2.1× the same quarter last year.
This period
27 (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
13.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+4.5
Same quarter last year
13
History used
1,827 days
the quarter ended 31 Dec 20248 earlier quartersnormal: 13.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Financials: Quarterly revenue change became public on 11 Mar 2025
Phathom Pharmaceuticals reported revenue of $29.7M for the quarter ended 31 Dec 2024, 43× the same quarter last year.
This period
$29.7M (the quarter ended 31 Dec 2024)
Normal quarter (median of 7 earlier)
$682K
Typical spread (median absolute deviation)
$682K
How far from its usual level
+28.7
Same quarter last year
$682K
History used
641 days
the quarter ended 31 Dec 20247 earlier quartersnormal: $682K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
19 Nov 2024confirmed
Confirmed across sources Institutional holdings and Filings + Financials
Phathom Pharmaceuticals(PHAT): reported revenue of $16.4M for the quarter ended 30 Sep 2024, against none in the same quarter last year, while it saw 25 13F filers open a new position in the quarter ended 30 Sep 2024, 1.9× the same quarter last year. Two unrelated kinds of activity within 7 days.
Financials: Quarterly revenue change, became public on 12 Nov 2024
Institutional holdings: Many funds opening a new position, became public on 14 Nov 2024
The quarter ended 30 Sep 2024 against the 6 quarters before it.
this quarterearliernormal: $341KSee the evidence (2 changes)
Financials: Quarterly revenue change became public on 12 Nov 2024
Phathom Pharmaceuticals reported revenue of $16.4M for the quarter ended 30 Sep 2024, against none in the same quarter last year.
This period
$16.4M (the quarter ended 30 Sep 2024)
Normal quarter (median of 6 earlier)
$341K
Typical spread (median absolute deviation)
$341K
How far from its usual level
+16.0
Same quarter last year
$0
History used
549 days
the quarter ended 30 Sep 20246 earlier quartersnormal: $341K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Institutional holdings: Many funds opening a new position became public on 14 Nov 2024
Phathom Pharmaceuticals saw 25 13F filers open a new position in the quarter ended 30 Sep 2024, 1.9× the same quarter last year.
This period
25 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
13.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+3.8
Same quarter last year
13
History used
1,735 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 13.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
18 Nov 2026Filings change
filed a director or officer change: Vice President, Finance and principal accounting officer Robert Breedlove resigned, effective Dec 4, 2026; no disagreement cited.
Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.
reported revenue of $39.5M for the quarter ended 30 Jun 2025, 5.4× the same quarter last year.
Same quarter last year: $7.3M; its normal quarter is $4.6M.
See the evidence
This period
$39.5M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$4.6M
Typical spread (median absolute deviation)
$4.6M
How far from its usual level
+5.1
Same quarter last year
$7.3M
History used
822 days
the quarter ended 30 Jun 20258 earlier quartersnormal: $4.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $28.5M for the quarter ended 31 Mar 2025, 15× the same quarter last year.
Same quarter last year: $1.9M; its normal quarter is $1.3M.
See the evidence
This period
$28.5M (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
$1.3M
Typical spread (median absolute deviation)
$1.3M
How far from its usual level
+14.2
Same quarter last year
$1.9M
History used
731 days
the quarter ended 31 Mar 20258 earlier quartersnormal: $1.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
saw 27 13F filers open a new position in the quarter ended 31 Dec 2024, 2.1× the same quarter last year, while it reported revenue of $29.7M for the quarter ended 31 Dec 2024, 43× the same quarter last year. Two unrelated kinds of activity within 21 days.
See the evidence (2 changes)
Institutional holdings: Many funds opening a new position became public on 14 Feb 2025
Phathom Pharmaceuticals saw 27 13F filers open a new position in the quarter ended 31 Dec 2024, 2.1× the same quarter last year.
This period
27 (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
13.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+4.5
Same quarter last year
13
History used
1,827 days
the quarter ended 31 Dec 20248 earlier quartersnormal: 13.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Financials: Quarterly revenue change became public on 11 Mar 2025
Phathom Pharmaceuticals reported revenue of $29.7M for the quarter ended 31 Dec 2024, 43× the same quarter last year.
This period
$29.7M (the quarter ended 31 Dec 2024)
Normal quarter (median of 7 earlier)
$682K
Typical spread (median absolute deviation)
$682K
How far from its usual level
+28.7
Same quarter last year
$682K
History used
641 days
the quarter ended 31 Dec 20247 earlier quartersnormal: $682K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
11 Mar 2025Financials change
reported revenue of $29.7M for the quarter ended 31 Dec 2024, 43× the same quarter last year.
Same quarter last year: $682K; its normal quarter is $682K.
See the evidence
This period
$29.7M (the quarter ended 31 Dec 2024)
Normal quarter (median of 7 earlier)
$682K
Typical spread (median absolute deviation)
$682K
How far from its usual level
+28.7
Same quarter last year
$682K
History used
641 days
the quarter ended 31 Dec 20247 earlier quartersnormal: $682K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
saw 27 13F filers open a new position in the quarter ended 31 Dec 2024, 2.1× the same quarter last year.
Same quarter last year: 13; its normal quarter is 13.5.
See the evidence
This period
27 (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
13.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+4.5
Same quarter last year
13
History used
1,827 days
the quarter ended 31 Dec 20248 earlier quartersnormal: 13.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported revenue of $16.4M for the quarter ended 30 Sep 2024, against none in the same quarter last year, while it saw 25 13F filers open a new position in the quarter ended 30 Sep 2024, 1.9× the same quarter last year. Two unrelated kinds of activity within 7 days.
See the evidence (2 changes)
Financials: Quarterly revenue change became public on 12 Nov 2024
Phathom Pharmaceuticals reported revenue of $16.4M for the quarter ended 30 Sep 2024, against none in the same quarter last year.
This period
$16.4M (the quarter ended 30 Sep 2024)
Normal quarter (median of 6 earlier)
$341K
Typical spread (median absolute deviation)
$341K
How far from its usual level
+16.0
Same quarter last year
$0
History used
549 days
the quarter ended 30 Sep 20246 earlier quartersnormal: $341K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Institutional holdings: Many funds opening a new position became public on 14 Nov 2024
Phathom Pharmaceuticals saw 25 13F filers open a new position in the quarter ended 30 Sep 2024, 1.9× the same quarter last year.
This period
25 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
13.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+3.8
Same quarter last year
13
History used
1,735 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 13.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
14 Nov 2024Institutional holdings change
saw 25 13F filers open a new position in the quarter ended 30 Sep 2024, 1.9× the same quarter last year.
Same quarter last year: 13; its normal quarter is 13.5.
See the evidence
This period
25 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
13.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+3.8
Same quarter last year
13
History used
1,735 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 13.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported revenue of $16.4M for the quarter ended 30 Sep 2024, against none in the same quarter last year.
See the evidence
This period
$16.4M (the quarter ended 30 Sep 2024)
Normal quarter (median of 6 earlier)
$341K
Typical spread (median absolute deviation)
$341K
How far from its usual level
+16.0
Same quarter last year
$0
History used
549 days
the quarter ended 30 Sep 20246 earlier quartersnormal: $341K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 12.0M shares sold short in the 15 Apr 2024 report, 2.5× the same report last year.
Same report last year: 4.9M; its normal report is 4.7M.
See the evidence
This period
12.0M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
4.7M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+4.3
Same report last year
4.9M
History used
1,628 days
the 15 Apr 2024 report24 earlier reportsnormal: 4.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.6M shares sold short in the 28 Mar 2024 report, 2.9× the same report last year.
Same report last year: 3.6M; its normal report is 4.4M.
See the evidence
This period
10.6M (the 28 Mar 2024 report)
Normal report (median of 24 earlier)
4.4M
Typical spread (median absolute deviation)
938K
How far from its usual level
+4.5
Same report last year
3.6M
History used
1,610 days
the 28 Mar 2024 report24 earlier reportsnormal: 4.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.4M shares sold short in the 15 Mar 2024 report, 3.4× the same report last year.
Same report last year: 3.1M; its normal report is 4.3M.
See the evidence
This period
10.4M (the 15 Mar 2024 report)
Normal report (median of 24 earlier)
4.3M
Typical spread (median absolute deviation)
926K
How far from its usual level
+4.5
Same report last year
3.1M
History used
1,597 days
the 15 Mar 2024 report24 earlier reportsnormal: 4.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.3M shares sold short in the 15 Feb 2024 report, 3.4× the same report last year.
Same report last year: 2.7M; its normal report is 4.2M.
See the evidence
This period
9.3M (the 15 Feb 2024 report)
Normal report (median of 24 earlier)
4.2M
Typical spread (median absolute deviation)
840K
How far from its usual level
+4.1
Same report last year
2.7M
History used
1,568 days
the 15 Feb 2024 report24 earlier reportsnormal: 4.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.6M shares sold short in the 31 Jan 2024 report, 3.8× the same report last year.
Same report last year: 2.3M; its normal report is 4.1M.
See the evidence
This period
8.6M (the 31 Jan 2024 report)
Normal report (median of 24 earlier)
4.1M
Typical spread (median absolute deviation)
840K
How far from its usual level
+3.6
Same report last year
2.3M
History used
1,553 days
the 31 Jan 2024 report24 earlier reportsnormal: 4.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3 insiders buy $191K of its shares on the open market within 30 days (3 filings).
Who bought: Curran Terrie, Nabulsi Azmi, Parikh Asit.
See the evidence (3 source records)
Independent buyers
3
Purchase filings (Form 4, code P)
3
Total bought
$191K
Window
13 Mar 2023 to 12 Apr 2023
Curran Terrie (President and Chief Executive) bought 12,919 shares of PHAT ($101,027)dated 7 Apr 2023, public 8 Apr 2023
Nabulsi Azmi (Chief Operating Officer) bought 10,000 shares of PHAT ($82,600)dated 11 Apr 2023, public 12 Apr 2023
Parikh Asit (director) bought 1,000 shares of PHAT ($7,550)dated 11 Apr 2023, public 12 Apr 2023
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
had 5.7M shares sold short in the 15 Sep 2022 report, 4.1× the same report last year.
Same report last year: 1.4M; its normal report is 3.2M.
See the evidence
This period
5.7M (the 15 Sep 2022 report)
Normal report (median of 24 earlier)
3.2M
Typical spread (median absolute deviation)
419K
How far from its usual level
+4.1
Same report last year
1.4M
History used
1,050 days
the 15 Sep 2022 report24 earlier reportsnormal: 3.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Fires on an 8-K with item 5.02 after 90 days without one.
Showing the newest 40 of 74 entries; narrow the window or the kind of data to see older ones.
Not listed: 182 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001783183
Ticker
PHAT
Domain
phathompharma.com
Hq location
NJ|FLORHAM PARK|07932 (1 unverified)
Lobbying client
phathom pharmaceuticals
Name
Phathom Pharmaceuticals, Inc.
Uei
KPGYDW3H7ZW6
Federal lobbying disclosures (LDA)3 records, 42 data points30 Mar 2021 to 30 Sep 2026
SEC Form 13F institutional holdings252 data points31 Dec 2019 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)135 records30 Sep 2019 to 18 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)514 data points31 Dec 2017 to 27 Oct 2026
SEC Form 4 insider transactions89 records, 296 data points30 Oct 2019 to 5 Nov 2025
FINRA short interest (twice monthly)503 data points31 Oct 2019 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)3556 data points25 Oct 2019 to 20 Nov 2026